Persian Medicine Products in Covid-19
Phase 3
- Conditions
- Covid-19.Covid-19RA01.0
- Registration Number
- IRCT20140617018126N2
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Over 18 years old patients hospitalized, with or suspected of COVID-19
Exclusion Criteria
Having liver, kidney and heart failure
History of immunodeficiency
Breastfeeding and pregnancy
Hypertension
Alcohol or drug addiction
A history of allergies to medicinal herbs
Patients with transplanted organs
Cor Pulmonale Patients
History of deep vein thrombosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: respiratory Count.
- Secondary Outcome Measures
Name Time Method C-reactive protein. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Intravenous blood test.;Lymphocytes. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Intravenous blood test.;White Blood Cells. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Intravenous blood test.